Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
FDA launches consolidated adverse event reporting system
Cancer Policy

FDA launches consolidated adverse event reporting system

March 20, 2026
Vol.52 No.11
By Claire Marie Porter
CBER Director Vinay Prasad dared to “say no to drugs”
Podcast

CBER Director Vinay Prasad dared to “say no to drugs”

March 18, 2026
Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
Regulatory News

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

March 13, 2026
Vol.52 No.10
By Claire Marie Porter
Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology
Regulatory News

Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology
Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.”

March 13, 2026
Vol.52 No.10
By Jacquelyn Cobb
FDA approves leucovorin for cerebral folate deficiency
Cancer Policy

FDA approves leucovorin for cerebral folate deficiency

March 13, 2026
Vol.52 No.10
By Claire Marie Porter
Drugs & Targets

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM

March 06, 2026
Vol.52 No.09
Drugs & Targets

FDA grants tentative approval for Lutetium Lu 177 dotatate

March 06, 2026
Vol.52 No.09
Cancer Policy

FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases

February 27, 2026
Vol.52 No.08
Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

February 27, 2026
Vol.52 No.08
Drugs & Targets

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

February 27, 2026
Vol.52 No.08

Posts navigation

12…55Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
    NCI Director Letai: “How aggressive can we be?”
  • A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
  • Early-onset colorectal cancer demands a new research playbook
  • Robert A. Winn named director of Fox Chase Cancer Center
  • CBER Director Vinay Prasad dared to “say no to drugs”

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account